CICC International maintains a "hold" rating on China Resources Pharmaceutical Group (01093.HK) and lowers the target price to 8.5 Hong Kong dollars.

Digiwin Financial News APP learned that CCB International released a research report stating that Stone Pharmaceutical Group (01093.HK) achieved a 6% quarterly increase in revenue to RMB 6.6 billion in the third quarter of 2025, mainly due to the digestion of the negative impact on traditional oncology products. Sales in all core therapeutic areas increased. However, net profit declined by 10% to RMB 964 million in the quarter, mainly due to a significant increase in operating expenses. The target price was lowered to HK$8.5, maintaining a "hold" rating. This target price corresponds to a 20x P/E ratio for 2026.